Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Tamsulosin 0.4 mg SR vs Harnal® OCAS in Healthy Fasting Subjects
NCT06558032Phase 1Completed
- Sponsor
- Dexa Medica
- Start
- Nov 2023
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of tamsulosin in benign prostatic hyperplasia (BPH) (2 arms), sponsored by Dexa Medica. Primary endpoints: Area Under the Plasma Concentration-Time Curve From Time Zero to Last Quantifiable Concentration at 72 hours and Maximum Plasma Concentration at 72 hours. Started Nov 2023; status: completed.
02
Drugs
tamsulosin
03
Conditions
benign prostatic hyperplasia (BPH)
Beyond the preview
Go deeper on NCT06558032.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06558032.